WO2013154511A1 - Formulations de comprimés pelliculés comprenant du dexibuprofène - Google Patents

Formulations de comprimés pelliculés comprenant du dexibuprofène Download PDF

Info

Publication number
WO2013154511A1
WO2013154511A1 PCT/TR2013/000110 TR2013000110W WO2013154511A1 WO 2013154511 A1 WO2013154511 A1 WO 2013154511A1 TR 2013000110 W TR2013000110 W TR 2013000110W WO 2013154511 A1 WO2013154511 A1 WO 2013154511A1
Authority
WO
WIPO (PCT)
Prior art keywords
formulation
cellulose
dexibuprofen
formulation according
active agent
Prior art date
Application number
PCT/TR2013/000110
Other languages
English (en)
Inventor
Mahmut Bilgic
Original Assignee
Mahmut Bilgic
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mahmut Bilgic filed Critical Mahmut Bilgic
Publication of WO2013154511A1 publication Critical patent/WO2013154511A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
    • A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose

Definitions

  • the present invention relates to formulations comprising dexibuprofen used in symptomatic treatment for prophylaxis of pain and inflammation associated with osteoarthritis, in symptomatic treatment of primary dysmenorrhea, in symptomatic treatment of all mild to moderate musculoskeletal system or dental pains.
  • Said formulations are characterized in being in film coated tablet form.
  • Dexibuprofen was first disclosed in the patent numbered US3385886. It was disclosed in said document that dexibuprofen is used in the treatment of painful joint inflammations seen in rheumatoid arthritis, Still's disease and osteoarthritis; various non-specific infection or rheumatic conditions affecting fibromuscular tissues and connective tissues; in treatment of rheumatic fever and sequelae.
  • Dexibuprofen is in 400 mg tablet form on the market.
  • Dexibuprofen is an anti-inflammatory drug having low melting point and low solubility.
  • low soluble formulations comprising dexibuprofen are prepared in tablet form, it is seen that they hardly and slowly disperse in body liquid when taken in body. Failure of tablet formulations comprising dexibuprofen to disperse in body fast and easily during use leads to results such as low absorption, low drug plasma level and thus low therapeutic activity.
  • the inventors have surprisingly seen that the formulations formulated in film tablet form and comprising dexibuprofen disperse homogeneously and fast in body and an efficient treatment is obtained due to high absorption they provide in the case that said formulations comprise cellulose-based diluent, cellulose-based disintegrant and cellulose-based binder and the ratio of these excipients to each other by weight is in the range of 85:2:0.5 to 10:0.5:2 respectively.
  • the first element of the invention is formulations comprising dexibuprofen and formulated in film tablet form which are characterized in that said formulations comprise cellulose-based diluent, cellulose-based disintegrant and cellulose-based binder and the ratio of these excipients to each other by weight is in the range of 85:2:0.5 to 10:0.5:2 respectively.
  • the present invention relates to formulations comprising dexibuprofen and formulated in film coated tablet form characterized in that said formulations comprise cellulose-based diluent, cellulose-based disintegrant and cellulose-based binder and the ratio of these excipients to each other by weight is in the range of 85:2:0.5 to 10:0.5:2 respectively.
  • the active agent dexibuprofen comprised in the formulations of the present invention can be in the form of its solvates, hydrates, esters, enantiomers, racemates, organic salts, inorganic salts, polymorphs, crystalline and amorphous forms or free form and/or combinations thereof.
  • a characteristic of the formulations of the present invention is that said formulations comprise the active agent dexibuprofenin the range of 20-80%, preferably in the range of 30-70%.
  • Another characteristic feature of the formulations of the present invention is that the ratio of the cellulose-based diluent, disintegrant and binder to each other by weight is in the range of 40: 1 :0.5 to 20: 1 :2 respectively.
  • the diluent in the present invention can be selected from a group comprising microcrystalline cellulose, silicified microcrystalline, cellulose acetate, modified cellulose and/or combinations thereof.
  • microcrystalline cellulose can be used as diluent in the formulations of the present invention.
  • the disintegrant in the formulation can be selected from a group comprising carboxymethyl cellulose calcium, carboxymethyl cellulose sodium, microcrystalline cellulose, croscarmellose sodium, hydroxypropyl cellulose, methyl cellulose or combinations thereof.
  • carboxymethyl cellulose calcium can be used as disintegrant in the formulations of the present invention.
  • the binder in the formulation can be selected form a group comprising ethyl cellulose, hydroxyethyl cellulose, hydroxymethyl cellulose, hydroxypropyl cellulose, hypromellose, hydroxypropyl methyl cellulose or a combination thereof.
  • hydroxypropyl methyl cellulose can be used as binder in the formulations prepared according to the present invention.
  • the ratio of microcrystalline cellulose, carboxymethyl cellulose calcium and hydroxypropyl methyl cellulose to each other by weight is preferably in the range of 85:2:0.5 to 10:0.5:2, more preferably in the range of 40: 1 :0.5 to 20: 1 :2 respectively.
  • formulations of the present invention comprise at least one pharmaceutically acceptable excipient in addition to the active agent dexibuprofen, diluent, disintegrant and binder.
  • the excipients that can be used in the formulations of the present invention can be selected from a group comprising anti-adhesive agent, glidant, lubricant, optionally coating agent or combinations thereof.
  • the formulations of the present invention do not adhere to the punches during preparation and they have proper flow characteristics in the case that they comprise an anti-adhesive agent in the range of 0.01% to 2%, preferably in the range of 0.05% to 1% and a glidant in the range of 0.5% to 5%, preferably in the range of 0.8% to 4% in proportion to total weight.
  • the formulation comprises an anti-adhesive agent in the range of 0.01 % to 2%, preferably in the range of 0.05% to 1% and a glidant in the range of 0.5% to 5%, preferably in the range of 0.8% to 4% in proportion to total weight.
  • the anti-adhesive agent to be used in the formulations of the present invention can be selected from a group comprising talc, stearates, colloidal silicon dioxide, sodium sulfate, starch, leucine or a combination thereof.
  • the glidant to be used in the formulations of the present invention can be selected from a group comprising magnesium silicate, silicon dioxide, colloidal silicon dioxide, starch, talc, tribasic calcium phosphate or a combination thereof.
  • the lubricant to be used in the formulations of the present invention can be selected from a group comprising calcium stearate, magnesium stearate, sodium stearyl fumarate, polyethylene glycol, PEG 6000, polyvinyl alcohol, potassium benzoate, sodium benzoate.
  • the film coating agent in the formulations of the present invention can be selected from a group comprising titanium dioxide, polyvinyl alcohol, polyethylene glycol, talc, lecithin or a combination thereof.
  • the film coating agent marketed under the name Opadry Yellow® can be used.
  • formulations of the present invention comprises at least another active agent in addition to dexibuprofen used as the active agent.
  • the second active agent that can be used in the formulations of the present invention can be selected from antibiotic, antiseptic, antipyretic, anti-inflammatory, muscle relaxant, analgesic, non-steroid anti-inflammatory, sympathomimetic drugs or combinations thereof.
  • the formulations of the present invention can preferably comprise an analgesic and/or antipyretic drug, more preferably paracetamol as the second active agent in addition to dexibuprofen used as the active agent.
  • the formulations of the present invention can preferably comprise a sympathomimetic drug, more preferably pseudoephedrine as the second active agent in addition to dexibuprofen used as the active agent.
  • the formulations prepared according to the present invention can comprise 20-80% dexibuprofen, 10-50% diluent, 0.5-3% disintegrant, 1-3.5% binder, 0.1-2% lubricant, 1-5% coating agent in proportion to total weight of unit dose.
  • dexibuprofen and the diluent are mixed, the mixture is granulated with a granulation solution comprising binder.
  • the obtained granules are dried, sieved and mixed with the disintegrant, anti-adhesive agent and glidant.
  • This mixture is lubricated with the lubricant and then tablet compression is started.
  • the tablets compressed are coated with the coating solution comprising coating agent.
  • the dexibuprofen formulations of the present invention can be used in symptomatic treatment for prophylaxis of pain and inflammation associated with osteoarthritis, in symptomatic treatment of primary dysmenorrhea, in symptomatic treatment of all mild to moderate musculoskeletal system or dental pains.
  • the formulation given below is prepared by wet granulation method.
  • Dexibuprofen and diluent mixture is granulated with a granulation solution comprising the binder.
  • the obtained granules are dried, sieved and mixed with the disintegrant, anti-adhesive agent and glidant.
  • This mixture is lubricated with the lubricant and then tablet compression is started.
  • the compressed tablets are coated with a coating solution comprising coating agent.

Abstract

L'invention concerne des formulations qui comprennent du dexibuprofène et qui conviennent au traitement symptomatique préventif de la douleur et de l'inflammation associées à l'arthrose, au traitement symptomatique de la dysménorrhée primaire, et au traitement symptomatique de toutes les douleurs légères à modérées, dentaires ou musculo-squelettiques. Ces formulations se caractérisent en ce qu'elles se présentent en comprimés pelliculés.
PCT/TR2013/000110 2012-04-13 2013-04-03 Formulations de comprimés pelliculés comprenant du dexibuprofène WO2013154511A1 (fr)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
TR2012/04302 2012-04-13
TR201204302 2012-04-13
TR201204564 2012-04-19
TR2012/04564 2012-04-19

Publications (1)

Publication Number Publication Date
WO2013154511A1 true WO2013154511A1 (fr) 2013-10-17

Family

ID=48614101

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/TR2013/000110 WO2013154511A1 (fr) 2012-04-13 2013-04-03 Formulations de comprimés pelliculés comprenant du dexibuprofène

Country Status (1)

Country Link
WO (1) WO2013154511A1 (fr)

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3385886A (en) 1961-02-02 1968-05-28 Boots Pure Drug Co Ltd Phenyl propionic acids
WO1992020334A1 (fr) * 1991-05-13 1992-11-26 The Boots Company Plc Composition pharmaceutique comprenant un sel d'ibuprofene
EP0607467A1 (fr) * 1992-12-01 1994-07-27 Spirig Ag Pharmazeutische Präparate Compositions pharmaceutiques à base de S(+)-Ibuprofène
WO2007069874A1 (fr) * 2005-12-16 2007-06-21 Hanmi Pharm. Co., Ltd. Dispersion solide comprenant un ingredient actif a bas point de fusion et comprime destine a l'administration orale comprenant cette dispersion solide
WO2008069938A2 (fr) * 2006-12-04 2008-06-12 Scolr Pharma, Inc. Procédé de formation d'un comprimé

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3385886A (en) 1961-02-02 1968-05-28 Boots Pure Drug Co Ltd Phenyl propionic acids
WO1992020334A1 (fr) * 1991-05-13 1992-11-26 The Boots Company Plc Composition pharmaceutique comprenant un sel d'ibuprofene
EP0607467A1 (fr) * 1992-12-01 1994-07-27 Spirig Ag Pharmazeutische Präparate Compositions pharmaceutiques à base de S(+)-Ibuprofène
WO2007069874A1 (fr) * 2005-12-16 2007-06-21 Hanmi Pharm. Co., Ltd. Dispersion solide comprenant un ingredient actif a bas point de fusion et comprime destine a l'administration orale comprenant cette dispersion solide
WO2008069938A2 (fr) * 2006-12-04 2008-06-12 Scolr Pharma, Inc. Procédé de formation d'un comprimé

Similar Documents

Publication Publication Date Title
JP5827952B2 (ja) 速効性と持続性を同時に有する薬剤学的組成物
CA2798090C (fr) Compositions pharmaceutiques de co-cristaux de tramadol et de coxibs
JP2009526840A (ja) 脂肪族アミンポリマーの医薬製剤及びそれらの製造方法
JP2009501785A (ja) 新規な調節放出性医薬製剤シクロオキシゲナーゼ酵素阻害剤
CZ225596A3 (en) Film-coated tablets of paracetamol and domperidon
JP2010520891A (ja) ネビラピンの徐放性製剤
WO2019219823A1 (fr) Dispersion solide contenant du ritonavir
CA2696977A1 (fr) Composition pharmaceutique amelioree contenant un agent anticonvulsif a base de pyrrolidone et son procede de preparation
KR20070046124A (ko) 활성 성분을 함유하는 위-정체 정제 형태의 제약 조성물
CA2833115C (fr) Compositions pharmaceutiques de raltegravir, procedes de preparation et utilisation de celles-ci
WO2013169218A1 (fr) Compositions pharmaceutiques de s-étodolac
WO2013154512A1 (fr) Formulations pharmaceutiques contenant du dexibuprofène
US20130085145A1 (en) Imatinib mesilate pharmaceutical tablet
WO2013154511A1 (fr) Formulations de comprimés pelliculés comprenant du dexibuprofène
JP6461142B2 (ja) イソニアジドの顆粒およびリファペンチンの顆粒を含むコーティング錠の形態の抗結核性の安定な医薬組成物ならびにその製造方法
WO2013095319A2 (fr) Formulations de flurbiprofène et de diacéréine
WO2013115737A2 (fr) Nouvelles compositions pharmaceutiques de flurbiprofène et glucosamine
EP2809305B1 (fr) Formulations pour comprimés bicouches de flurbiprofène et glucosamine
JP2017171626A (ja) プロピオン酸系非ステロイド性消炎鎮痛薬を含有した医薬組成物
EP2793853A2 (fr) Formulations pharmaceutiques de flurbiprofène et glucosamine
RU2603469C2 (ru) Таблетка с контролируемым высвобождением для перорального введения и способ ее приготовления
WO2023219592A2 (fr) Composition de comprimé comprenant du paracétamol, de la chlorphéniramine et de l'acide ascorbique
JP2009167110A (ja) 無包装状態において安定性に優れた塩酸サルポグレラート含有経口投与製剤
US20140275239A1 (en) Dronedarone Formulation
WO2014007777A1 (fr) Formulations combinées de ains sous forme de gélule

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 13728547

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 13728547

Country of ref document: EP

Kind code of ref document: A1